Abstract | BACKGROUND: METHODS: This randomized, double-blind, placebo-controlled, multicenter study evaluated the effects of intravenous salvianolate on the achievement of complete epicardial and myocardial reperfusion after PCI, defined as thrombolysis in myocardial infarction flow grade 3 and thrombolysis in myocardial infarction myocardial perfusion grade 3. We also measured plasma total creatine kinase-mass band fraction (CK-MB)-estimated infarct size and echocardiography-derived left ventricular ejection fraction and recorded the 30-day clinical and safety outcomes. A total of 536 patients presenting with acute STEMI were randomized to receive either an i.v. infusion of salvianolate (n=265) or placebo (n=271). RESULTS:
Salvianolate administration exerted beneficial effects on coronary microcirculation. There was a trend of reduced myocardial infarct size in the salvianolate group compared to the placebo group (P=0.070), although no significant difference in left ventricular ejection fraction was found between the two groups. CONCLUSIONS:
Salvianolate administration is associated with improved myocardial perfusion in patients with STEMI undergoing PCI. A larger study is required to assess the impact of this therapy on clinical cardiac outcomes.
|
Authors | Li Shen, Rende Xu, Jiasheng Yin, Hao Lu, Shuning Zhang, Zheyong Huang, Dong Huang, Hongying Liu, Juying Qian, Junbo Ge |
Journal | Annals of translational medicine
(Ann Transl Med)
Vol. 8
Issue 18
Pg. 1185
(Sep 2020)
ISSN: 2305-5839 [Print] China |
PMID | 33241034
(Publication Type: Journal Article)
|
Copyright | 2020 Annals of Translational Medicine. All rights reserved. |